Sitagliptin

Sitagliptin is a DPP‑4 inhibitor with modest HbA1c reduction and cardiovascular neutrality; it has no demonstrated heart failure outcome benefit. DPP-4 inhibitors may in fact exacerbate heart failure symptoms through oedema worsening. This is not the best drug for Mr. Green.

Please go back and re-consider. 

  • How many leisure time cards could you choose? [undo]
  • MSA [undo]
  • Prefiere sentarse solo. [undo]
  • ΚΛΙΝΙΚΗ ΕΞΕΤΑΣΗ [undo]
  • Descripción de las células 1 [undo]
  • Παραμονή του stent και παρακολούθηση [undo]
  • Start B12 administration [undo]
  • Θα παραπέμψεις τον ασθενή να υποβληθεί σε βρογχοσκόπηση [undo]
  • Privacy risk [undo]
  • Exenatide [undo]
  • Ρήξη ουρητήρα [undo]
  • Explain the procedure [undo]
  • Συμπέρασμα [undo]
  • Metformin [undo]
  • ΑΠΟΤΕΛΕΣΜΑΤΑ ΒΙΟΧΗΜΙΚΩΝ ΕΞΕΤΑΣΕΩΝ [undo]
  • Opțiunea 2: Pentru a identifica și manipula corespunzător materialele periculoase din laborator [undo]
  • Θα τον στείλεις σε θωρακοχειρουργό [undo]
  • Insulin detemir [undo]
  • Option 2 [undo]
  • Carros? [undo]
  • Πολυμεράση Taq [undo]
  • Vârful rădăcinii de ceapă [undo]
  • Examination [undo]
  • ΑΙΜΟΡΡΑΓΙΑ ΑΠΟ ΓΕΣ [undo]
  • Game Over [undo]
  • Πρωτεϊνοσύνθεση [undo]
  • Game Over [undo]
  • Quit therapy for now [undo]
  • Ωτοσκόπηση [undo]
  • Explain the procedure and ask for his consensus [undo]
  • Node 3: Address each concern in detail [undo]
  • Gastrointestinal symptoms [undo]
  • Osmosis [undo]
  • Ζητώ καρυότυπο [undo]
  • Respuesta 2 [undo]
  • Amlodipine (Calcium Channel Blocker) Adverse Effects [undo]
  • Genome Sequencing [undo]
  • Tell the patient to change devices without giving proper guidance. [undo]
  • Sitagliptin [undo]

Map: Michael Green_GEMD_2 (1116)
Node: 21125
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway